Literature DB >> 825165

Value of megavolt therapy in gastric carcinoma.

E Nordman.   

Abstract

45 cases of carcinoma of the stomach were treated with megavolt irradiation in the Radiotherapy Clinic of Turku University Central Hospital and in the Radiotherapy Department of the Central Hospital in Jyvâskylâ. 41 of the patients had histological or cytological verification of the tumour, 4 only an X-ray diagnosis. One-year survival of patients with local inoperable tumour was 10 out of 19, two-year survival 5 out of 19 and three-year survival 3 out of 19. Relief of symptoms was obtained in 6 cases out of 19 for one year, for two years in 4 cases out of 19, and for three years, in 3 cases. It is suggested that local inoperable carcinomas of the stomach should be treated by 5 000 rads. One-year survival of patients presenting with abdominal metastases was only 2 out of 26 and the two-year survival 1 out of 26. It appears that radiotherapy of carcinoma of the stomach, which already has metastases, is not indicated.

Entities:  

Mesh:

Year:  1976        PMID: 825165

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  3 in total

1.  Clinical outcome of palliative radiotherapy for locally advanced symptomatic gastric cancer in the modern era.

Authors:  Jeremy Tey; Bok Ai Choo; Cheng Nang Leong; En Yun Loy; Lea Choung Wong; Keith Lim; Jiade Jay Lu; Wee Yao Koh
Journal:  Medicine (Baltimore)       Date:  2014-11       Impact factor: 1.889

Review 2.  Palliative radiotherapy for gastric cancer: a systematic review and meta-analysis.

Authors:  Jeremy Tey; Yu Yang Soon; Wee Yao Koh; Cheng Nang Leong; Bok Ai Choo; Francis Ho; Balamurugan Vellayappan; Keith Lim; Ivan Wk Tham
Journal:  Oncotarget       Date:  2017-04-11

3.  Palliative radiotherapy in symptomatic locally advanced gastric cancer: A phase II trial.

Authors:  Jeremy Tey; Huili Zheng; Yu Y Soon; Cheng N Leong; Wee Y Koh; Keith Lim; Jimmy B Y So; Asim Shabbir; Ivan W K Tham; Jiade Lu
Journal:  Cancer Med       Date:  2019-02-20       Impact factor: 4.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.